HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 288/5/G907    most recent 00420.2004v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (29) Citing Articles via Google Scholar Google Scholar Articles by Yoshiji, H. Articles by Fukui, H. Search for Related Content PubMed PubMed Citation Articles by Yoshiji, H. Articles by Fukui, H.

LIVER AND BILIARY TRACT

Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats

¹Third Department of Internal Medicine, Nara Medical University, Nara; and ²Third Department of Internal Medicine, School of Medicine, Kagawa University, Kagawa, Japan

Submitted 22 September 2004 ; accepted in final form 29 November 2004

It is widely recognized that activated hepatic stellate cells (HSC) play a pivotal role in development of liver fibrosis. A platelet-derived growth factor (PDGF) is the most potent mitogen for HSC. The aim of this study was to examine the effect of imatinib mesylate (STI-571, Gleevec), a clinically used PDGF receptor (PDGFR) tyrosine kinase inhibitor, on development of experimental liver fibrosis. The rat model of pig serum-induced hepatic fibrosis was used to assess the effect of daily oral administration of STI-571 on the indexes of fibrosis. STI-571 markedly attenuated development of liver fibrosis and hepatic hydroxyproline and serum fibrosis markers. The number of -smooth muscle actin-positive cells and mRNA expression of ₂-(I)-procollagen, tissue inhibitor of metalloproteinases-1, and transforming growth factor- were also significantly suppressed by STI-571. Our in vitro study showed that STI-571 markedly attenuated PDGF-BB-induced proliferation and migration and -SMA and ₂-(I)-procollagen mRNA of activated HSC in a dose-dependent manner. STI-571 also significantly attenuated PDGF-BB-induced phosphorylation of PDGFR-, MEK1/2, and Akt in activated HSC. Because STI-571 is widely used in clinical practice, it may provide an effective new strategy for antifibrosis therapy.

platelet-derived growth factor; hepatic stellate cell

This article has been cited by other articles:

				J. H. W. Distler and O. Distler Imatinib as a novel therapeutic approach for fibrotic disorders Rheumatology, January 1, 2009; 48(1): 2 - 4. [Full Text] [PDF]

				V. Gioni, T. Karampinas, G. Voutsinas, A. E. Roussidis, S. Papadopoulos, N. K. Karamanos, and D. Kletsas Imatinib Mesylate Inhibits Proliferation and Exerts an Antifibrotic Effect in Human Breast Stroma Fibroblasts Mol. Cancer Res., May 1, 2008; 6(5): 706 - 714. [Abstract] [Full Text] [PDF]

				M. Azuma, Y. Nishioka, Y. Aono, M. Inayama, H. Makino, J. Kishi, M. Shono, K. Kinoshita, H. Uehara, F. Ogushi, et al. Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1243 - 1250. [Abstract] [Full Text] [PDF]

				P. Stock, D. Monga, X. Tan, A. Micsenyi, N. Loizos, and S. P.S. Monga Platelet-derived growth factor receptor-{alpha}: a novel therapeutic target in human hepatocellular cancer Mol. Cancer Ther., July 1, 2007; 6(7): 1932 - 1941. [Abstract] [Full Text] [PDF]